Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Throat Lozenges Market

ID: MRFR/HC/43100-HCR
200 Pages
Nidhi Mandole
Last Updated: April 24, 2026

China Throat Lozenges Market Research Report By Type (Hard candy lozenges, Soft lozenges, Compressed lozenges), By Ingredient (Menthol, Mint, Eucalyptus oil, Peppermint oil, Honey Ginger, Lemon, Others) and By Indication (Sore throat, Cough And Cold, Throat diseases) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Throat Lozenges Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Industrial Automation & Equipment, BY Type (USD Million)
  49.     4.1.1 hard candy lozenges
  50.     4.1.2 soft lozenges
  51.     4.1.3 compressed lozenges
  52.   4.2 Industrial Automation & Equipment, BY Ingredient (USD Million)
  53.     4.2.1 menthol
  54.     4.2.2 mint
  55.     4.2.3 eucalyptus oil
  56.     4.2.4 peppermint oil
  57.     4.2.5 honey & ginger
  58.     4.2.6 lemon
  59.     4.2.7 others
  60.   4.3 Industrial Automation & Equipment, BY Indication (USD Million)
  61.     4.3.1 sore throat
  62.     4.3.2 cough and cold
  63.     4.3.3 throat diseases
  64. 5 SECTION V: COMPETITIVE ANALYSIS
  65.   5.1 Competitive Landscape
  66.     5.1.1 Overview
  67.     5.1.2 Competitive Analysis
  68.     5.1.3 Market share Analysis
  69.     5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  70.     5.1.5 Competitive Benchmarking
  71.     5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  72.     5.1.7 Key developments and growth strategies
  73.       5.1.7.1 New Product Launch/Service Deployment
  74.       5.1.7.2 Merger & Acquisitions
  75.       5.1.7.3 Joint Ventures
  76.     5.1.8 Major Players Financial Matrix
  77.       5.1.8.1 Sales and Operating Income
  78.       5.1.8.2 Major Players R&D Expenditure. 2023
  79.   5.2 Company Profiles
  80.     5.2.1 Reckitt Benckiser (GB)
  81.       5.2.1.1 Financial Overview
  82.       5.2.1.2 Products Offered
  83.       5.2.1.3 Key Developments
  84.       5.2.1.4 SWOT Analysis
  85.       5.2.1.5 Key Strategies
  86.     5.2.2 Procter & Gamble (US)
  87.       5.2.2.1 Financial Overview
  88.       5.2.2.2 Products Offered
  89.       5.2.2.3 Key Developments
  90.       5.2.2.4 SWOT Analysis
  91.       5.2.2.5 Key Strategies
  92.     5.2.3 Pfizer (US)
  93.       5.2.3.1 Financial Overview
  94.       5.2.3.2 Products Offered
  95.       5.2.3.3 Key Developments
  96.       5.2.3.4 SWOT Analysis
  97.       5.2.3.5 Key Strategies
  98.     5.2.4 Haleon (GB)
  99.       5.2.4.1 Financial Overview
  100.       5.2.4.2 Products Offered
  101.       5.2.4.3 Key Developments
  102.       5.2.4.4 SWOT Analysis
  103.       5.2.4.5 Key Strategies
  104.     5.2.5 Boehringer Ingelheim (DE)
  105.       5.2.5.1 Financial Overview
  106.       5.2.5.2 Products Offered
  107.       5.2.5.3 Key Developments
  108.       5.2.5.4 SWOT Analysis
  109.       5.2.5.5 Key Strategies
  110.     5.2.6 Church & Dwight (US)
  111.       5.2.6.1 Financial Overview
  112.       5.2.6.2 Products Offered
  113.       5.2.6.3 Key Developments
  114.       5.2.6.4 SWOT Analysis
  115.       5.2.6.5 Key Strategies
  116.     5.2.7 Novartis (CH)
  117.       5.2.7.1 Financial Overview
  118.       5.2.7.2 Products Offered
  119.       5.2.7.3 Key Developments
  120.       5.2.7.4 SWOT Analysis
  121.       5.2.7.5 Key Strategies
  122.     5.2.8 GlaxoSmithKline (GB)
  123.       5.2.8.1 Financial Overview
  124.       5.2.8.2 Products Offered
  125.       5.2.8.3 Key Developments
  126.       5.2.8.4 SWOT Analysis
  127.       5.2.8.5 Key Strategies
  128.     5.2.9 MediNatura (DE)
  129.       5.2.9.1 Financial Overview
  130.       5.2.9.2 Products Offered
  131.       5.2.9.3 Key Developments
  132.       5.2.9.4 SWOT Analysis
  133.       5.2.9.5 Key Strategies
  134.   5.3 Appendix
  135.     5.3.1 References
  136.     5.3.2 Related Reports
  137. 6 LIST OF FIGURES
  138.   6.1 MARKET SYNOPSIS
  139.   6.2 CHINA MARKET ANALYSIS BY TYPE
  140.   6.3 CHINA MARKET ANALYSIS BY INGREDIENT
  141.   6.4 CHINA MARKET ANALYSIS BY INDICATION
  142.   6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
  143.   6.6 RESEARCH PROCESS OF MRFR
  144.   6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
  145.   6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
  146.   6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
  147.   6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
  148.   6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
  149.   6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
  150.   6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INGREDIENT, 2024 (% SHARE)
  151.   6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INGREDIENT, 2024 TO 2035 (USD Million)
  152.   6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 (% SHARE)
  153.   6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 TO 2035 (USD Million)
  154.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  155. 7 LIST OF TABLES
  156.   7.1 LIST OF ASSUMPTIONS
  157.     7.1.1
  158.   7.2 China MARKET SIZE ESTIMATES; FORECAST
  159.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  160.     7.2.2 BY INGREDIENT, 2025-2035 (USD Million)
  161.     7.2.3 BY INDICATION, 2025-2035 (USD Million)
  162.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  163.     7.3.1
  164.   7.4 ACQUISITION/PARTNERSHIP
  165.     7.4.1

China Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Type (USD Million, 2025-2035)

  • hard candy lozenges
  • soft lozenges
  • compressed lozenges

Industrial Automation & Equipment By Ingredient (USD Million, 2025-2035)

  • menthol
  • mint
  • eucalyptus oil
  • peppermint oil
  • honey & ginger
  • lemon
  • others

Industrial Automation & Equipment By Indication (USD Million, 2025-2035)

  • sore throat
  • cough and cold
  • throat diseases

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions